Assessing the efficacy of magnesium oxide and riboflavin as preventative treatment of migraines in pregnancy.

Abstract

PURPOSE:

The purpose of this study is to assess the efficacy of magnesium oxide (MgO) alone and, secondarily, MgO plus riboflavin as preventive treatment of migraines in pregnancy. We hypothesize that MgO alone will be effective for the majority of patients and, when clinically indicated, the addition of riboflavin will result in further benefit.

METHODS:

This was a retrospective cohort study of pregnant patients treated for migraines between 2015 and 2020. We evaluated pre-/post-differences in the following primary outcomes: migraine frequency, severity, and duration. Secondary outcomes included associated migraine symptoms.

RESULTS:

Of 203 total patients, 117 received MgO alone and 86 received MgO plus riboflavin. There were no significant differences in baseline demographics between the two groups. There was a statistically significant decrease in migraine frequency, severity, and duration in the groups receiving MgO alone and MgO plus riboflavin (p < 0.01 for all). In total, 154 patients reported migraine-associated symptoms, of which 119 (77%) improved after treatment, 18 (12%) did not improve, and 17 (11%) patients' data were missing. The MgO plus riboflavin group had a lower gestational age at treatment initiation and was more likely to receive treatment prior to pregnancy (p < 0.01). Significant differences were observed for several baseline migraine symptoms, including photophobia, phonophobia, nausea, and vomiting, which were more common in the group receiving MgO plus riboflavin (p < 0.05 for all).

CONCLUSION:

Migraine frequency, severity, and duration all decreased with MgO alone and MgO plus riboflavin in this pregnancy cohort. Associated symptoms also significantly decreased for both groups.

• Authors: Genevieve R Mazza, Claribel Solorio, Alice M Stek, Laura A Kalayjian, Melissa L Wilson, Brian J Gordon
• Journal: Archives of gynecology and obstetrics (Arch Gynecol Obstet) Vol. 308 Issue 6 Pg. 1749-1754 (Dec 2023) ISSN: 1432-0711 [Electronic] Germany
• PMID: 36495328 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Chemical References

• Magnesium Oxide
• Riboflavin

Topics

• Humans
• Pregnancy
• Female
• Magnesium Oxide (therapeutic use)
• Retrospective Studies
• Treatment Outcome
• Migraine Disorders (drug therapy, prevention & control)
• Riboflavin (therapeutic use)